跳至主要内容
临床试验/2022-503037-63-00
2022-503037-63-00已完成1 期

A two-part, open-label study to assess the pharmacokinetics, pharmacodynamics and safety of single doses of inhaled and intravenously administered D,L lysine acetylsalicylate • glycine (LASAG) in healthy adult subjects: Study Part A follows a randomized, cross-over design to compare three dose levels of inhaled LASAG to one dose level of intravenously administered LASAG and Study Part B follows a single group design to investigate a XXXXX LASAG inhalation solution.

Aspiair GmbH1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2023年5月19日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
Aspiair GmbH
入组人数
28
试验地点
1

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Aspiair GmbH
申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Sebastian Canisius

Scientific

Aspiair GmbH

研究点 (1)

Loading locations...

相似试验

已完成
2 期
ilotinib treatment cessation studyChronic Myeloid Leukemia
JPRN-jRCT2080222098ovartis Pharma117
进行中(未招募)
1 期
A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment.
EUCTR2012-003186-18-GBovartis Pharma Services AG163
进行中(未招募)
不适用
A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment.
EUCTR2012-003186-18-ESovartis Farmacéutica S.A.117
进行中(未招募)
1 期
A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment.Ph+ chronic myeloid leukemia (CML)MedDRA version: 19.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864
EUCTR2012-003186-18-BEovartis Pharma Services AG117
进行中(未招募)
1 期
A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment.Ph+ chronic myeloid leukemia (CML)MedDRA version: 14.1Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864
EUCTR2012-003186-18-GRovartis Pharma Services AG117